Orlistat
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Orlistat: From Obesity Management to Hypervitaminosis
One-Sentence Summary
Orlistat is a pancreatic lipase inhibitor originally used for weight management, working by blocking dietary fat absorption in the gut. The TxGNN model predicts a mechanistic association with Hypervitaminosis (fat-soluble vitamin excess), but this is currently based on model prediction alone, with no supporting clinical trials or literature identified in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no data provided) |
| Predicted New Indication | Hypervitaminosis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| US Market Status | Not marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not directly available in this evidence pack (marked as a data gap), but the repurposing rationale supplied alongside the prediction describes orlistat as a pancreatic lipase inhibitor that blocks intestinal hydrolysis and absorption of dietary fat.
The proposed link to hypervitaminosis is unusual in direction: orlistat’s well-documented side effect is malabsorption/deficiency of fat-soluble vitamins (A, D, E, K), not excess. The rationale itself frames this as a hypothesis derived by reversing a known adverse-effect pathway — if blocking fat absorption reduces fat-soluble vitamin uptake, it could theoretically be relevant to conditions of vitamin excess rather than deficiency. This is explicitly noted as not the original design intent of the drug, and the high TxGNN score likely reflects the model detecting the existing orlistat–fat-soluble-vitamin pharmacological connection in the knowledge graph, rather than an independent, validated new mechanism.
Given the inverted logic (deficiency-causing drug proposed for an excess condition) and the complete absence of clinical trial or literature evidence, the mechanistic plausibility should be treated as speculative pending expert pharmacological review.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No licenses on file — the drug is currently not marketed (未上市) with 0 registered authorizations.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications and drug interaction data are marked as blocking data gaps in this evidence pack and could not be included.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN model score (L5, no clinical trials or literature), the drug is not currently marketed in this jurisdiction, and the mechanistic rationale is a speculative reversal of a known adverse effect rather than an established or plausible therapeutic pathway.
To proceed, the following is needed:
- TFDA label warnings/contraindications (blocking data gap — required before any S1 safety review)
- Verified mechanism of action (MOA) documentation from DrugBank
- Independent pharmacological/expert review of the deficiency-vs-excess mechanistic logic before pursuing further evidence collection
- Literature or preclinical search specifically targeting orlistat and fat-soluble vitamin excess conditions
- Confirmation of original approved indication(s), currently missing from this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.